12 research outputs found
Temporal expression of Dmp53 and SNAMA isoforms and their relation to genotoxic stress.
A dissertation submitted to the Faculty of Science, University of the Witwatersrand, in fulfilment of the requirements for the degree of Master of Science. Johannesburg, 2015.RBBP6 is an E3 Ubiquitin ligase protein with a U-box motif. It interacts with p53 and Rb and is linked to several cellular functions. SNAMA is the Drosophila RBBP6 homolog, but is less characterized than its vertebrate counterparts. Gene expression studies on Drosophila have a potential to advance the knowledge on molecular mechanism underlying genotoxic stress. Previous studies have shown that SNAMA plays a critical role as an apoptosis suppressor and possibly in responses to genotoxic stress. The molecular basis for this is, however, unknown. Initially, two isoforms were identified by bioinformatics and one (Snama A) experimentally as well. Here, we confirm experimentally the existence of the second isoform (Snama B). We also show that these are differentially expressed during development and when the organism undergoes genotoxic stress. Total RNA samples were used to demonstrate gene expression by using Reverse Transcriptase Polymerase Chain Reaction. Using samples collected at different stages of development and from adult flies treated with the DNA damaging agent, irinotecan, it is shown that these isoforms are differentially expressed throughout development and upon genotoxic stress. This knowledge may help to understand the functional role SNAMA plays in normal physiology and in response to genotoxic stress. Furthermore, the results show that SNAMA is involved in a potentially beneficial intervention whereby the glycolytic pathway is bypassed by the addition of methyl pyruvate
Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches
The burden of breast cancer continues to increase worldwide as it remains the most diagnosed tumor in females and the second leading cause of cancer-related deaths. Breast cancer is a heterogeneous disease characterized by different subtypes which are driven by aberrations in key genes such as BRCA1 and BRCA2, and hormone receptors. However, even within each subtype, heterogeneity that is driven by underlying evolutionary mechanisms is suggested to underlie poor response to therapy, variance in disease progression, recurrence, and relapse. Intratumoral heterogeneity highlights that the evolvability of tumor cells depends on interactions with cells of the tumor microenvironment. The complexity of the tumor microenvironment is being unraveled by recent advances in screening technologies such as high throughput sequencing; however, there remain challenges that impede the practical use of these approaches, considering the underlying biology of the tumor microenvironment and the impact of selective pressures on the evolvability of tumor cells. In this review, we will highlight the advances made thus far in defining the molecular heterogeneity in breast cancer and the implications thereof in diagnosis, the design and application of targeted therapies for improved clinical outcomes. We describe the different precision-based approaches to diagnosis and treatment and their prospects. We further propose that effective cancer diagnosis and treatment are dependent on unpacking the tumor microenvironment and its role in driving intratumoral heterogeneity. Underwriting such heterogeneity are Darwinian concepts of natural selection that we suggest need to be taken into account to ensure evolutionarily informed therapeutic decisions
Increased expression of plakoglobin is associated with upregulated MAPK and PI3K/AKT signalling pathways in early resectable pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancer types, and it is associated with a 5‑year survival rate of <10% due to limited early detection methods and ineffective therapeutic options. Thus, an improved understanding of the mechanisms involved in the early stages of PDAC tumorigenesis is crucial in order to identify potential novel diagnostic and therapeutic targets. The most common signalling aberrations in PDAC occur in the Wnt/Notch signalling pathway, as well as within the epidermal growth factor receptor (EGFR) pathway and its associated ligands, EGF and transforming growth factor‑β. In addition, the RAS family of oncogenes, which act downstream of EGFR, are found mutated in most pancreatic cancer samples. Plakoglobin, a component of the EGFR signalling pathway, serves an important role in normal cell adhesion; however, its role in PDAC is largely unknown. The present study used transcriptome sequencing and focussed proteome microarrays to identify dysregulated genes and proteins in PDAC. The presence of upregulated plakoglobin expression levels was identified as a distinguishing feature between the PDAC microenvironment and normal pancreatic tissue. Furthermore, plakoglobin was demonstrated to be associated with the differential upregulation of the PI3K/AKT and MAPK signalling pathways in the tumour microenvironment, which suggested that it may serve an important role in PDAC tumourigenesis.The South African
National Research Foundation, the South African Medical
Research Council and the National Research Foundation.http://www.spandidos-publications.com/olhj2020Surger
Exploiting the molecular subtypes and genetic landscape in pancreatic cancer: the quest to find effective drugs
Pancreatic Ductal Adenocarcinoma (PDAC) is a very lethal disease that typically presents at an advanced stage and is non-compliant with most treatments. Recent technologies have helped delineate associated molecular subtypes and genetic variations yielding important insights into the pathophysiology of this disease and having implications for the identification of new therapeutic targets. Drug repurposing has been evaluated as a new paradigm in oncology to accelerate the application of approved or failed target-specific molecules for the treatment of cancer patients. This review focuses on the impact of molecular subtypes on key genomic alterations in PDAC, and the progress made thus far. Importantly, these alterations are discussed in light of the potential role of drug repurposing in PDAC
Downregulation of the let‑7 family of microRNAs may promote insulin receptor/insulin‑like growth factor signalling pathways in pancreatic ductal adenocarcinoma
Downregulation of the let‑7 family of microRNAs may promote insulin receptor/insulin‑like growth factor signalling pathways in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is
an aggressive cancer type characterized by dysregulated
cell signalling pathways and resistance to treatment. The
insulin‑like growth factor (IGF) signalling pathway has
been identified to have a role in tumour progression and
therapy resistance. However, its regulatory roles in PDAC
have remained to be fully elucidated. In the present study,
dysregulated microRNAs (miRNAs) in PDAC were explored
with a focus on those that may be involved in regulating the
insulin/IGF signalling pathway. A total of 208 patients were
recruited, comprising 112 patients with PDAC, 50 patients
with chronic pancreatitis (CP) and 46 subjects as a control
group (CG). miRNA‑specific quantitative PCR assays were
used to measure 300 candidate miRNAs. The Student's
t‑test was applied to compare miRNA regulation between
cancer patients and controls with a false discovery rate
correction using Bonferroni‑type comparison procedures.
The DIANA‑mirPath v.3 tool and HMDD v3.0 were used to
identify miRNA‑mRNA interactions within specific pathways.
In patients with PDAC, 42 miRNAs were significantly
upregulated and 42 were downregulated compared to the CG
(P<0.01). In the PDAC vs. CP analysis, 16 significantly (P<0.01)
upregulated and 16 downregulated miRNAs were identified.
Of note, members of the let‑7 family of miRNAs were downregulated and were indicated to target several components of
the insulin receptor (INSR)/IGF pathway, including receptors
and binding proteins, for upregulation and thus, may enable
the activation of the pathway. Downregulation of the let‑7
family may help promote the INSR/IGF pathway in PDAC. It may thus be an effective target for the development of INSR/
IGF pathway‑specific treatment strategies.The South African National Research Foundation and South African Medical Research Council.http://www.spandidos-publications.com/olam2021Surger
Polyethyleneglycol-Betulinic Acid (PEG-BA) Polymer-Drug Conjugate Induces Apoptosis and Antioxidation in a Biological Model of Pancreatic Cancer
Pancreatic cancer (PC) is one of the most aggressive solid malignancies with poor treatment response and low survival rates. Herbal medicines such as betulinic acid (BA) have shown potential in treating various solid tumours, but with limitations that can be circumvented by polymer-drug conjugation. Polyethylene glycol-BA (PEG-BA) polymer-drug conjugate has previously shown selective anticancer activity against PC cells. Here, we elucidate the mechanism of cell death and the cell death pathway, anti-inflammatory and antioxidant activities of PEG-BA. PEG-BA induced apoptotic cell death by arresting MIA-PaCa-2 cells in the Sub-G1 phase of the cell cycle compared with BA and untreated cells (39.50 ± 5.32% > 19.63 ± 4.49% > 4.57 ± 0.82%). NFκB/p65 protein expression was moderately increased by PEG-BA (2.70 vs. 3.09 ± 0.42 ng/mL; p = 0.1521). However, significant (p TNF (23.72 ± 1.03) and CASPASE 3 (12,059.98 ± 1.74) compared with untreated cells was notable. The antioxidant potential of PEG-BA was greater (IC50 = 15.59 ± 0.64 µM) compared with ascorbic acid (25.58 ± 0.44 µM) and BA-only (>100 µM) and further confirmed with the improved reduction of hydroperoxide levels compared with BA-only (518.80 ± 25.53 µM vs. 542.43 ± 9.70 µM). In conclusion, PEG-BA activated both the intrinsic and extrinsic pathways of apoptosis and improved antioxidant activities in PC cells, suggesting enhanced anticancer activity upon conjugation
Transient expression of Interleukin-21 in the second hit of acute pancreatitis may potentiate immune paresis in severe acute pancreatitis
OBJECTIVES : Interleukin-21 (IL-21) is a cytokine associated with tissue inflammation, autoimmune and infectious diseases. Organ dysfunction and death can occur in patients with acute pancreatitis (AP) in two distinct clinical phases. Initially, a systemic inflammatory response syndrome may be followed by systemic sepsis from infected pancreatic necrosis, known as the “second hit.” The expression and possible role of IL-21 in AP has not been established.
METHODS : Thirty-six patients with mild, moderate, and severe AP (SAP) were enrolled. Peripheral blood samples of patients were drawn on days 7, 9, 11, and 13. Reverse transcription–polymerase chain reaction and enzyme-linked immunosorbent assay were performed to determine the expression and concentration of IL-21.
RESULTS : Interleukin-21 mRNA levels increased significantly at day 9 in severe (P = 0.002) pancreatitis compared with both the mild and control patient groups. At the protein level, IL-21 was elevated in SAP patients compared with those with mild pancreatitis, although this was not significant. Furthermore, day 9 IL-21 was elevated in septic SAP patients and patients with pancreatic necrosis.
CONCLUSIONS : Interleukin-21 is transiently elevated in SAP compared with the mild/moderate group, and hence IL-21 may contribute to the immune imbalance that occurs in AP.Grants from SAGES (Abbott Research Award),
Discovery Foundation, Wits Donald Gordon Medical Centre, and The
University of the Witwatersrand Individual Research Grant
(001283844110151211055142) and Seed Funding Grant
(001251844110151211050000000000000000 4550).http://www.pancreasjournal.com2020-01-01hj2019Surger
Anti-cancer and immunomodulatory activity of a polyethylene glycol-betulinic acid conjugate on pancreatic cancer cells
Drug delivery systems involving polymer therapeutics enhance drug potency by improved
solubility and specificity and may assist in circumventing chemoresistance in pancreatic cancer (PC).
We compared the effectiveness of the naturally occurring drug, betulinic acid (BA), alone and in a
polymer conjugate construct of polyethylene glycol (PEG), (PEG–BA), on PC cells (MIA PaCa-2), a
normal cell line (Vero) and on peripheral blood mononuclear cells (PBMCs). PEG–BA, was tested
for its effect on cell death, immunomodulation and chemoresistance-linked signalling pathways.
The conjugate was significantly more toxic to PC cells (p < 0.001, IC50 of 1.35 0.11 M) compared
to BA (IC50 of 12.70 0.34 M), with a selectivity index (SI) of 7.28 compared to 1.4 in Vero cells.
Cytotoxicity was confirmed by increased apoptotic cell death. PEG–BA inhibited the production of
IL-6 by 4–5.5 fold compared to BA-treated cells. Furthermore, PEG–BA treatment of MIA PaCa-2 cells
resulted in the dysregulation of crucial chemoresistance genes such as WNT3A, TXNRD1, SLC2A1
and GATA3. The dysregulation of chemoresistance-associated genes and the inhibition of cytokines
such as IL-6 by the model polymer construct, PEG–BA, holds promise for further exploration in
PC treatment.SUPPLEMAENTARY MATERIAL : Figure S1: Line graph showing the effect of BA and PEG–BA IL-6; Figure S2: Effect of BA and PEG–BA on IL-17A, IFN- , TNF- , IL-10, IL-6, IL-4 and IL-2; Figure S3: The 96-plate layout of the human signal transduction RT2 profiler PCR array panel with the position of the genes; Table S1: Full names of dysregulated genes.The National Research Foundation of South Africa and the South African Medical Research Council.https://www.mdpi.com/journal/lifeam2022Chemistr
SWATH-MS based proteomic profiling of pancreatic ductal adenocarcinoma tumours reveals the interplay between the extracellular matrix and related intracellular pathways.
Pancreatic cancer accounts for 2.8% of new cancer cases worldwide and is projected to become the second leading cause of cancer-related deaths by 2030. Patients of African ancestry appear to be at an increased risk for pancreatic ductal adenocarcinoma (PDAC), with more severe disease and outcomes. The purpose of this study was to map the proteomic and genomic landscape of a cohort of PDAC patients of African ancestry. Thirty tissues (15 tumours and 15 normal adjacent tissues) were obtained from consenting South African PDAC patients. Optimisation of the sample preparation method allowed for the simultaneous extraction of high-purity protein and DNA for SWATH-MS and OncoArray SNV analyses. We quantified 3402 proteins with 49 upregulated and 35 downregulated proteins at a minimum 2.1 fold change and FDR adjusted p-value (q-value) ≤ 0.01 when comparing tumour to normal adjacent tissue. Many of the upregulated proteins in the tumour samples are involved in extracellular matrix formation (ECM) and related intracellular pathways. In addition, proteins such as EMIL1, KBTB2, and ZCCHV involved in the regulation of ECM proteins were observed to be dysregulated in pancreatic tumours. Downregulation of pathways involved in oxygen and carbon dioxide transport were observed. Genotype data showed missense mutations in some upregulated proteins, such as MYPN, ESTY2 and SERPINB8. Approximately 11% of the dysregulated proteins, including ISLR, BP1, PTK7 and OLFL3, were predicted to be secretory proteins. These findings help in further elucidating the biology of PDAC and may aid in identifying future plausible markers for the disease